Tirzepatide 30mg
Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors: a 39-amino-acid synthetic peptide based on the native GIP sequence with modifications conferring GLP-1 receptor co-agonism. A C20 fatty-diacid moiety linked through a glutamic acid and two mini-PEG spacers enhances albumin binding and in-vitro stability. Supplied strictly for in-vitro research and laboratory use only. Not for human or animal use.
Strength
Select Option
2+ save 5% · 5+ save 10% · 10+ save 20%
- Free Priority shipping on US orders over $100
- Ships same day on orders before 2 PM MST
- Plain, secure packaging
- Third-party tested — lot TIR-20260811-02 at 99.85% purity
Batch Tracking
Batch #
TIR-20260811-02
Tested
2026-08-23
Purity
99.85%
Method
RP-HPLC (214 nm)
Mechanism of Action
In engineered receptor-expressing cell systems, tirzepatide activates GIPR and GLP-1R. Willard et al. (2020) reported GIPR signaling resembling native GIP, while GLP-1R signaling favored cAMP generation over beta-arrestin recruitment and produced less GLP-1R internalization than GLP-1.
Properties
CAS Number
2023788-19-2
Molecular Formula
C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight
4813.53 Da
Half-Life
~5 days (human, subcutaneous)
Storage
Store lyophilized at -20°C. Reconstituted at 2-8°C, use within 30 days.
Shipping & Delivery
- Same-day dispatch on orders placed before 2 PM MST (Arizona — no daylight saving).
- US shipping from $5. Free Priority on orders $100+ (before discounts).
- Plain, unmarked packaging — no branding or product names on the outside.
- Ships to all 50 states, DC, Puerto Rico & the U.S. Virgin Islands; tracking emailed on every order.
Quality & Testing
- Independently tested by Bioviridian Inc. — identity by LC-MS/MS, purity by RP-HPLC (214 nm).
- Measured at 99.85% purity on lot TIR-20260811-02.
- USA-based; dispatched from Phoenix, Arizona.
- Supplied strictly for in-vitro laboratory research — not for human use.
Research Applications
References & Citations
(4)Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.
Schneck K, Urva S
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard FS, Douros JD, Gabe MBN, et al.
Structural determinants of dual incretin receptor agonism by tirzepatide
Sun B, Willard FS, Feng D, et al.
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Samms RJ, Christe ME, Collins KA, et al.
Other strengths
Research Use Only
This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.